Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
IDEAYA Biosciences, Inc. (IDYA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update • Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of June 30, 2023 anticipated to fund operations into 2027 • Initiated Phase 2/3 registrational trial for darovasertib and crizotinib combination in first-line HLA-A2 negative metastatic UM, and also initiated a separate Phase 2 clinical trial to evaluate single-agent darovasertib as neoadjuvant and adjuvant therapy for primary UM • Targeting darovasertib clinical program updates in Q4 2023, including ctDNA data from Phase 2 MUM trial at ESMO 2023, as well as prevalence of HLA-A2 / serotypes and clinical data update for darovasertib as neoadjuvant therapy in primary UM •..."
08/09/2023 144 Form 144 - Report of proposed sale of securities:
07/10/2023 144 Form 144 - Report of proposed sale of securities:
07/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/30/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Open Market Sales Agreement, by and between the Company and Jefferies LLC",
"Opinion of Latham & Watkins LLP"
06/09/2023 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
05/16/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma  Amended clinical trial collaboration and supply agreements with Pfizer to support evaluation of IDEAYA’s planned Phase 2/3 registrational clinical trial to evaluate Daro + Crizo in 1L MUM  Initiating Phase 2/3 registrational trial in Q2 2023 for darovasertib and crizotinib combination in First-Line HLA-A2 negative MUM, with median PFS as primary endpoint for potential AA South San Francisco, CA, May 16, 2023 – IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has amended its ..."
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update • Strong balance sheet of $351.2 million of cash, cash equivalents and marketable securities as of March 31, 2023 supplemented by $188.7 million estimated net proceeds from closing of underwritten public offering on April 27, 2023, anticipated to fund operations into 2027 • Initiating Phase 2/3 registrational trial in Q2 2023 of darovasertib and crizotinib combination in First-Line HLA-A2 negative MUM, with median PFS as primary endpoint for potential accelerated approval • Reported compelling darovasertib program Phase 2 clinical efficacy, including in First-Line and Any-Line MUM, and additional clinical efficacy as neoadjuvant therapy in primary UM • Targeting da..."
04/27/2023 8-K Quarterly results
04/24/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/24/2023 8-K Quarterly results
04/24/2023 8-K Quarterly results
04/14/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/24/2023 SC 13G BIOTECHNOLOGY VALUE FUND L P reports a 5.1% stake in IDEAYA Biosciences, Inc.
03/07/2023 10-K Annual Report for the period ended December 31, 2022
03/07/2023 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update • Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of December 31, 2022 is anticipated to fund planned operations into 2026 • Planning regulatory update on potential registration-enabling clinical trial for darovasertib / crizotinib combination in MUM following scheduled FDA meeting in Q1 2023 • Targeting mid-year 2023 darovasertib / crizotinib clinical efficacy update with approximately 20 first-line MUM patients, including confirmed ORR and median PFS; program goals are >20% confirmed ORR and >5 months median PFS • Targeting interim clinical efficacy update from ongoing investigator sponsored trial for darovasertib as neoadjuvant ther..."
02/27/2023 SC 13G ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 5.4% stake in IDEAYA Biosciences, Inc.
02/14/2023 SC 13G/A Avidity Partners Management LP reports a 7.9% stake in IDEAYA Biosciences, Inc.
02/14/2023 SC 13G/A Boxer Capital, LLC reports a 4.6% stake in IDEAYA, Inc.
02/14/2023 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 4.6% stake in IDEAYA Biosciences, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 SC 13G/A FEDERATED HERMES, INC. reports a 6% stake in IDEAYA BIOSCIENCES, INC.
01/31/2023 SC 13G/A BlackRock Inc. reports a 7.4% stake in IDEAYA BIOSCIENCES INC
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update • Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations into 2026 • Reported Phase 2 interim clinical data for darovasertib and crizotinib combination in MUM; subject to FDA guidance, targeting initiation of potential registrational trial for Daro + Crizo in MUM in Q1 2023 • Reported preliminary clinical proof-of-concept supporting potential darovasertib use in adjuvant uveal melanoma; targeting initiation of company-sponsored trial for Daro in neoadjuvant UM in Q4 2022 • Initiated IDE397 Phase 2 monotherapy expansion cohorts and Phase 1 combination dose escalation ..."
10/27/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
09/19/2022 8-K Asset disposition
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among IDEAYA Biosciences, Inc. and J.P. Morgan Securities LLC, Jefferies LLC, and Citigroup Global Markets Inc., as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP"
09/15/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/14/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/14/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy